Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG

This study has been completed.
Sponsor:
Collaborators:
Molecular Insights Pharmaceuticals
Information provided by (Responsible Party):
Bennett Chin, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT01730417
First received: November 7, 2012
Last updated: November 20, 2012
Last verified: November 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2011
  Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Publications:
Chin BB, Grasfeder L, Femia F, Hillier S, Petry N, Armor T, Stubbs J, Stabin M, Babich J, Kronauge J. Phase 1 clinical trial results for high specific activity Ultratrace Iobenguane I 123. J Nucl Med. 2012;53:1516.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):